Show
Sort by
-
- Conference Paper
- C3
- open access
Drug response profiling informs personalized bridging to cell therapy for patients with relapsed/refractory acute lymphoblastic leukemia
-
- Journal Article
- A1
- open access
The prognostic value of IKZF1(plus) in B‐cell progenitor acute lymphoblastic leukemia : results from the EORTC 58951 trial
-
- Journal Article
- A1
- open access
CircRNAs dysregulated in juvenile myelomonocytic leukemia : CircMCTP1 stands out
-
- Journal Article
- A1
- open access
Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia
-
- Journal Article
- A1
- open access
Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study
-
CNS-3 status remains an independent adverse prognosis factor in children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation : results of EORTC Children Leukemia Group study 58951
-
Pediatric randomized trial EORTC CLG 58951 : outcome for adolescent population with acute lymphoblastic leukemia
-
- Conference Paper
- C3
- open access
NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia : a good prognostic subtype identified in a collaborative international study
-
Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL)
-
Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia
-
Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia : proof of concept study
-
- Journal Article
- A1
- open access
The long non-coding RNA landscape in juvenile myelomonocytic leukemia
-
Exploring the long non-coding RNA landscape in juvenile myelomonocytic leukemia
-
Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia : results of the EORTC CLG 58881 and 58951 trials
-
- Journal Article
- A1
- open access
Prolonged versus standard native E-coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma : final results of the EORTC-CLG randomized phase III trial 58951
-
LIN28B is overexpressed in pediatric leukemia and regulates LNCRNA H19
-
LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia
-
Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials
-
Impact of age and treatment group in childhood high hyperdiploid low risk B-cell acute lymphoblastic leukemia (ALL) : results of the CLG-EORTC 58951 study
-
Genetic characterization and therapeutic targeting of MYC translocated pediatric T-cell acute lymphoblastic leukemia
-
LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19
-
The long non-coding RNA H19 is regulated by LIN28B
-
Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia
-
IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Chrildren's Leukemia Group study 58951
-
- Journal Article
- A1
- open access
CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol
-
Prognostic relevance of BTLA/CD200 deletion in pediatric pre-B cell acute lymphoblastic leukemia
-
Update: Potential prognostic impact of BTLA/CD200 in Pre-B-ALL
-
LIN28B defines an aggressive subtype of juvenile myelomonocytic leukemia
-
An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions
-
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group
-
Prognostic relevance of CD200/BTLA deletions in pediatric precursor-B cell acute lymphoblastic leukemia treated according to the EORTD-CLG 58951 protocol
-
Dexamethasone (6 mg/m²/day) and prednisolone (60 mg/m²/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial
-
Potential prognostic impact of BTLA/CD200 in Pre B-ALL
-
Update: Potential prognostic impact of BTLA/CD200 in Pre-B-ALL
-
Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results
-
Improved risk stratification and outcome prediction in children with average risk 1 precursor-B acute lymphoblastic leukemia using a 19-microRNA signature
-
Improved risk-stratification and outcome prediction in children with average risk precursor-B acute lymphoblastic leukemia using a 19-microRNA signature
-
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition
-
NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951
-
Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies
-
The TLX1 oncogene drives aneuploidy in T cell transformation
-
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008
-
Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: Long term results of the EORTC CLG 58881 trial
-
Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCR β-HOXA rearrangement : a study of the Groupe Francophone de Cytogénétique Hématologique
-
Cardiofaciocutaneous (CFC) syndrome associated with muscular coenzyme Q(10) deficiency
-
The TCRB-HOXA rearrangement in T-ALL leads to a specific increase of the alternative HOXA10b transcript
-
PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience
-
Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951
-
t(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Francais de Cytogenetique Hematologique (GFCH)
-
HOX11L2 expression linked to t(5;14)(q35;q32) is not associated with poor prognosis in childhood T-ALL treated in EORTC trials 58 881 and 58 951
-
Long-term results of three randomized trials (58831,58832,58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report.